Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
15 drugs in development
By Therapeutic Area
top 6
R&D Momentum
77/100
Pipeline Velocity
37/100
Trial Completion Rate
91/100
Pipeline Concentration
20/100
Pipeline Freshness
0/100
Strategic Signals
Activity
Last 14 days
EDEN Intracardiac Electrogram Recording and Classifying System
Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies
VINTAGE (Ventricular Intramyocardial Navigation for Tachycardia Ablation Guided by Electrograms) Using Commercial Off-The-Shelf (COTS) Catheters, Early Feasibility Study
Matched Related Donor Non-myeloablative Hematopoietic Cell Transplantation With Alemtuzumab, 400 cGy TBI, and Abatacept for Sickle Cell Disease and Beta-Thalassemia
A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease
Multi-scale Phenotyping of Heart Failure: From Precision Phenotyping to Population Inference (PHENO-HEART)
Natural History of Bronchiectasis
Asthma Sample Collection Protocol
Genes Involved in Lipid Disorders
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)